您即将离开沛嘉医疗中文官网。
您刚才点击了进入另一网站的链接。如果继续,您可能会进入由第三方运行的网站。 我们不负责对非沛嘉医疗中文官网上的内容进行审核与管控,亦不会对您在非沛嘉医疗中文网上的任何商业交易或事物承担任何责任。您使用其他网站时,必须遵循该网站的使用条款及隐私声明。 其他网站上的部分产品和信息可能并未在您所在地区或国家获得批准。
取消
继续
Brief News on Innovation
Company News Brief News on Innovation
NEW AV21 SPECIFICATION: PEIJIA MEDICAL’S TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) SYSTEM APPROVED BY THE NMPA
2024-04-19 10:58:12

On April 18, 2024, new AV21 specification of TaurusOne® and TaurusElite® TAVR systems, developed by the Company, has been approved by the NMPA. The new specification has the following advantages: 1) Precise fit: specially designed for the smaller aortic root structure of Chinese patients 2) Large EOA: supra-annular valve design; higher radial force; lower risk of PPM 3) Waist design: ensures coronary artery safety 4) Short stent: with a stent height of 40.5mm, it poses a low risk of ascending aorta dissection after implantation.


Top